Entrada Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 5, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 5, 2024

TRDA$4.69-4.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share amounts)

Common Stock · AdditionalPaid‑inCapital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
Balances at December 31, 2022	31,394,767	$3	$402,893	$(2,057)	$(188,285)	$212,554
Issuance of common stock upon exercise of stock options	18,344	—	129	—	—	129
Vesting of early exercised options	10,153	—	26	—	—	26
Vesting of restricted stock units	91,859	—	—	—	—	—
Issuance of common stock in connection with the Vertex Agreement	1,618,613	—	19,407	—	—	19,407
Stock‑based compensation	—	—	2,755	—	—	2,755
Other comprehensive income (loss)	—	—	—	1,415	—	1,415
Net loss	—	—	—	—	(6,674)	(6,674)
Balances at March 31, 2023	33,133,736	$3	$425,210	$(642)	$(194,959)	$229,612
Issuance of common stock upon exercise of stock options	46,175	—	257	—	—	257
Vesting of early exercised options	9,468	—	25	—	—	25
Purchase of common stock under the employee stock purchase plan	16,314	—	186	—	—	186
Stock‑based compensation	—	—	3,119	—	—	3,119
Other comprehensive income (loss)	—	—	—	(363)	—	(363)
Net loss	—	—	—	—	(25,928)	(25,928)
Balances at June 30, 2023	33,205,693	$3	$428,797	$(1,005)	$(220,887)	$206,908
Issuance of common stock upon exercise of stock options	80,630	—	368	—	—	368
Vesting of early exercised options	7,391	—	21	—	—	21
Vesting of restricted stock units	46,502	—	—	—	—	—
Stock‑based compensation	—	—	3,396	—	—	3,396
Other comprehensive income (loss)	—	—	—	509	—	509
Net income	—	—	—	—	35,461	35,461
Balances at Balances at September 30, 2023	33,340,216	$3	$432,582	$(496)	$(185,426)	$246,663

Common Stock · AdditionalPaid‑inCapital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
Balances at December 31, 2023	33,437,296	$3	$437,132	$195	$(194,970)	$242,360
Issuance of common stock upon exercise of stock options	30,888	—	206	—	—	206
Vesting of early exercised options	3,411	—	13	—	—	13
Vesting of restricted stock units	132,458	—	—	—	—	—
Stock‑based compensation	—	—	3,733	—	—	3,733
Other comprehensive loss	—	—	—	(441)	—	(441)
Net income	—	—	—	—	23,496	23,496
Balances at March 31, 2024	33,604,053	$3	$441,084	$(246)	$(171,474)	$269,367
Issuance of common stock upon exercise of stock options	166,155	—	1,104	—	—	1,104
Vesting of early exercised options	3,411	—	13	—	—	13
Vesting of restricted stock units	11,490	—	—	—	—	—
Purchase of common stock under the employee stock purchase plan	20,384	—	263	—	—	263
Issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs of $392	3,367,003	1	99,607	—	—	99,608
Stock‑based compensation	—	—	4,622	—	—	4,622
Other comprehensive loss	—	—	—	(83)	—	(83)
Net income	—	—	—	—	55,031	55,031
Balances at June 30, 2024	37,172,496	$4	$546,693	$(329)	$(116,443)	$429,925
Issuance of common stock upon exercise of stock options	63,228	—	381	—	—	381
Vesting of early exercised options	3,253	—	12	—	—	12
Vesting of restricted stock units	161,522	—	—	—	—	—
Stock‑based compensation	—	—	4,860	—	—	4,860
Other comprehensive income (loss)	—	—	—	1,301	—	1,301
Net loss	—	—	—	—	(14,032)	(14,032)
Balances at September 30, 2024	37,400,499	$4	$551,946	$972	$(130,475)	$422,447

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.